Vitrolife

Vitrolife Excellence in reproductive health Today, we support customers worldwide - always with sustainability in mind. We are your committed partner for the IVF journey.

Vitrolife is committed to supporting successful treatment outcomes and has been dedicated to IVF since 1994, when the field was still young. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for fertility clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genet

ic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors. Our vision is to enable people to fulfil the dream of having a healthy baby), and we achieve this by supporting our customers in delivering successful treatment outcomes. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. We can help you maximise success. – Together. All the way. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.

18/06/2026

💡Exciting new data suggests that Gx-IVF can be a perfect fit for ICSI procedures

At ALPHA 2026, a sibling-oocyte study exploring the embryological outcomes on the effect of Gx-IVF versus HEPES buffer during ICSI was presented.

Listen to Matija Krunic, PhD Senior Clinical Embryologist, Brussels IVF, Belgium about the implications of the results.

Learn more about Gx media here:
https://www.vitrolife.com/products/ivf-media--oil/gx-media/?utm_source=Social&utm_medium=Facebook&utm_campaign=Gx%20IVF

📣 ESHRE 2026 is fast approaching, and we are proud to announce that for the fifth year in a row, we will host our Academ...
16/06/2026

📣 ESHRE 2026 is fast approaching, and we are proud to announce that for the fifth year in a row, we will host our Academy Studio at our booth!

Throughout the congress, we will offer a range of insightful presentations, all hosted by David O'Rourke, Clinical Support Manager EMEIA, Vitrolife Group.

Warm welcome!

11/06/2026

💡For your advanced maternal age patients or those with DOR, how does your treatment plan or protocol differ to help improve the chances of a successful pregnancy?

Introducing Part 2 of the Mini-Series: How Terra Fertility is elevating care and supporting outcomes with EmbryoScope and PGT-A Plus

Data from a recently published clinical study showed a significant increase in detection of euploid/diploid embryos in embryos with confirmed atypical PN using Time-lapse technology with EmbryoScope and PGT-A with ploidy detection.

Read the full blog post here:
👉https://ow.ly/cwAt50Zak5O

A recent study comparing Gx Media to culture media from another brand found that use of Gx Media, with an antioxidant-en...
08/06/2026

A recent study comparing Gx Media to culture media from another brand found that use of Gx Media, with an antioxidant-enriched formulation, led to significantly higher euploidy rates and lower rates of whole chromosome aneuploidy.

Three antioxidants have been added to our gamete-handling, fertilisation, and culture media to form a protective barrier against oxidative stress. Together, they are integrated in Gx Media, supporting all stages of the process. For optimal results, use the complete system.

Read more here:
👉 https://ow.ly/EiLf50Z8J4c

💡Reducing subjectivity in embryo selection through AI-assisted assessmentIn our recent article, inspired by findings fro...
04/06/2026

💡Reducing subjectivity in embryo selection through AI-assisted assessment

In our recent article, inspired by findings from a new clinical publication, Mitchell Rosen, MD, shares perspectives on how AI-assisted embryo assessment may help reduce subjectivity in embryo selection, support clinical decision-making, and provide added value in complex cases and embryologist training.

The article also explores how technologies such as iDAScore® may help minimise variability and support a more standardised approach to embryo evaluation across IVF laboratories.

Read the article here:
👉 https://ow.ly/g6xU50Z5ycB

03/06/2026

We are excited to present Part 1 of the mini-series: How Terra Fertility is elevating care and supporting outcomes with EmbryoScope and PGT-A Plus.

Read the full blog post to learn key clinical (and workflow) advantages of both EmbryoScope and PGT-A Plus compared to current standard of care.

💡How does your practice evaluate new technologies for implementation? What criteria is most important?

👉https://ow.ly/Se6M50Z6YN8

Quality all the way 💡At Vitrolife Group, we all work to achieve the same goal, whatever our role – to help people fulfil...
01/06/2026

Quality all the way 💡

At Vitrolife Group, we all work to achieve the same goal, whatever our role – to help people fulfil the dream of having a healthy baby. To do this, we aim to deliver the best products for the entire IVF journey that have consistent performance and guaranteed quality.

To provide an unbroken chain of innovative high-quality products we focus on quality from initial research and development to production, distribution and clinical and scientific support.

Read more about our four cornerstones of our quality processes here: 👉 https://ow.ly/xyOX50Wvamj

💡Why does consistency in embryo assessment matter?In our recent article, inspired by a new clinical publication, Mark La...
29/05/2026

💡Why does consistency in embryo assessment matter?

In our recent article, inspired by a new clinical publication, Mark Larman, VP Medical Affairs at Vitrolife Group North America, highlights the importance of standardisation in embryo assessment and how AI-assisted decision-support tools such as iDAScore®, may help reduce variability between embryologists, support laboratory performance, and contribute to improved clinical outcomes.

Read the article here: https://ow.ly/p7jc50Z5st7

💡Quality all the wayBehind every safe and reliable product is a commitment to doing more than what’s expected. With our ...
21/05/2026

💡Quality all the way

Behind every safe and reliable product is a commitment to doing more than what’s expected. With our beyond-industry standard MEA and strict quality control processes, we build confidence through science, precision and a constant dedication to safety.

Explore our industry-leading MEA and cell-count here:
https://ow.ly/P8ip50Z2Crm

We're excited to announce that we will be participating in the 42nd Annual Meeting of the European Society of Human Repr...
20/05/2026

We're excited to announce that we will be participating in the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London.

Join us at booth C07 during the congress - we look forward to connecting with you and sharing knowledge. More details about our presence and activities at ESHRE 2026 will be announced soon, so stay tuned for updates.

Adress

Gustaf Werners Gata 2
Västra Frölunda
42132

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när Vitrolife postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Genvägar

Dela

Typ